REDEFINE-3
randomised, double-blind, 2-armed, parallel-group, placebo-controlled trial primarily intended to assess the cardiovascular safety of CagriSema 2.4 mg/2.4 mg versus placebo, both administered subcutaneously (s.c.) once weekly in participants with obesity and established CVD
- Stage
- followup
- Medicine
- CagriSema
- Population
- ASCVD
- Phase
- III
- First Patient In
- 18 April 2023
- Last Patient In
- 18 December 2024
- Last Patient Last Visit
- 1 September 2027
National Lead
prof. dr. C. Tack
Study Director
dr. A.M. Otten
Cardioloog
Office Contact
